

Senate
Study
Bill
1264
-
Introduced


SENATE
FILE
_____


BY
(PROPOSED
COMMITTEE
ON


STATE
GOVERNMENT
BILL
BY


CHAIRPERSON
DANIELSON)


A
BILL
FOR


An
Act
relating
to
the
use
of
experimental
treatments
for
1


patients
with
a
terminal
illness.
2


BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
3


TLSB
1642XC
(1)
86


tr/nh



S.F.
_____


Section
1.
NEW
SECTION
.
144E.1
Title.
1


This
chapter
shall
be
known
and
may
be
cited
as
the
“Right
2


to
Try
Act”
.
3


Sec.
2.
NEW
SECTION


.
144E.2
Definitions.
4


As
used
in
this
chapter:
5


1.
“Eligible
patient”
means
an
individual
who
meets
all
of
6


the
following
conditions:
7


a.
Has
a
terminal
illness,
attested
to
by
the
patient’s
8


treating
physician.
9


b.
Has
considered
all
other
treatment
options
approved
by
10


the
United
States
food
and
drug
administration.
11


c.
Has
received
a
recommendation
from
the
individual’s
12


physician
for
an
investigational
drug,
biological
product,
or
13


device.
14


d.
Has
given
written
informed
consent
for
the
use
of
the
15


investigational
drug,
biological
product,
or
device.
16


e.
Has
documentation
from
the
individual’s
physician
that
17


the
individual
meets
the
requirements
of
this
subsection.
18


2.
“Investigational
drug,
biological
product,
or
device”
19


means
a
drug,
biological
product,
or
device
that
has
20


successfully
completed
phase
1
of
a
United
States
food
and
drug
21


administration-approved
clinical
trial
but
has
not
yet
been
22


approved
for
general
use
by
the
United
States
food
and
drug
23


administration
and
remains
under
investigation
in
a
United
24


States
food
and
drug
administration-approved
clinical
trial.
25


3.
“Terminal
illness”
means
a
progressive
disease
or
medical
26


or
surgical
condition
that
entails
significant
functional
27


impairment,
that
is
not
considered
by
a
treating
physician
to
28


be
reversible
even
with
administration
of
treatments
approved
29


by
the
United
States
food
and
drug
administration,
and
that,
30


without
life-sustaining
procedures,
will
soon
result
in
death.
31


4.
“Written
informed
consent”
means
a
written
document
that
32


is
signed
by
the
patient,
a
parent
of
a
minor
patient,
or
a
33


legal
guardian
or
other
legal
representative
of
the
patient
and
34


attested
to
by
the
patient’s
treating
physician
and
a
witness
35


-1-


LSB
1642XC
(1)
86


tr/nh
1/
6





S.F.
_____


and
that
includes
all
of
the
following:
1


a.
An
explanation
of
the
products
and
treatments
approved
by
2


the
United
States
food
and
drug
administration
for
the
disease
3


or
condition
from
which
the
patient
suffers.
4


b.
An
attestation
that
the
patient
concurs
with
the
5


patient’s
treating
physician
in
believing
that
all
products
6


and
treatments
approved
by
the
United
States
food
and
drug
7


administration
are
unlikely
to
prolong
the
patient’s
life.
8


c.
Clear
identification
of
the
specific
proposed
9


investigational
drug,
biological
product,
or
device
that
the
10


patient
is
seeking
to
use.
11


d.
A
description
of
the
best
and
worst
potential
outcomes
12


of
using
the
investigational
drug,
biological
product,
or
13


device
and
a
realistic
description
of
the
most
likely
outcome.
14


The
description
shall
include
the
possibility
that
new,
15


unanticipated,
different,
or
worse
symptoms
might
result
16


and
that
death
could
be
hastened
by
use
of
the
proposed
17


investigational
drug,
biological
product,
or
device.
The
18


description
shall
be
based
on
the
treating
physician’s
19


knowledge
of
the
proposed
investigational
drug,
biological
20


product,
or
device
in
conjunction
with
an
awareness
of
the
21


patient’s
condition.
22


e.
A
statement
that
the
patient’s
health
plan
or
third-party
23


administrator
and
provider
are
not
obligated
to
pay
for
any
24


care
or
treatments
consequent
to
the
use
of
the
investigational
25


drug,
biological
product,
or
device,
unless
they
are
26


specifically
required
to
do
so
by
law
or
contract.
27


f.
A
statement
that
the
patient’s
eligibility
for
hospice
28


care
may
be
withdrawn
if
the
patient
begins
curative
treatment
29


with
the
investigational
drug,
biological
product,
or
device
30


and
that
care
may
be
reinstated
if
this
treatment
ends
and
the
31


patient
meets
hospice
eligibility
requirements.
32


g.
A
statement
that
the
patient
understands
that
the
33


patient
is
liable
for
all
expenses
consequent
to
the
use
of
34


the
investigational
drug,
biological
product,
or
device
and
35


-2-


LSB
1642XC
(1)
86


tr/nh
2/
6



S.F.
_____


that
this
liability
extends
to
the
patient’s
estate
unless
1


a
contract
between
the
patient
and
the
manufacturer
of
the
2


investigational
drug,
biological
product,
or
device
states
3


otherwise.
4


Sec.
3.
NEW
SECTION


.
144E.3
Manufacturer
rights.
5


1.
A
manufacturer
of
an
investigational
drug,
biological
6


product,
or
device
may
make
available
and
an
eligible
patient
7


may
request
the
manufacturer’s
investigational
drug,
biological
8


product,
or
device
under
this
chapter.
This
chapter
does
not
9


require
a
manufacturer
of
an
investigational
drug,
biological
10


product,
or
device
to
provide
or
otherwise
make
available
the
11


investigational
drug,
biological
product,
or
device
to
an
12


eligible
patient.
13


2.
A
manufacturer
described
in
subsection
1
may
do
any
of
14


the
following:
15


a.
Provide
an
investigational
drug,
biological
product,
or
16


device
to
an
eligible
patient
without
receiving
compensation.
17


b.
Require
an
eligible
patient
to
pay
the
costs
of,
or
the
18


costs
associated
with,
the
manufacture
of
the
investigational
19


drug,
biological
product,
or
device.
20


Sec.
4.
NEW
SECTION


.
144E.4
Treatment
coverage.
21


1.
This
chapter
does
not
expand
the
coverage
required
of
an
22


insurer
under
Title
XIII,
subtitle
1.
23


2.
A
health
plan,
third-party
administrator,
or
24


governmental
agency
may
provide
coverage
for
the
cost
of
an
25


investigational
drug,
biological
product,
or
device,
or
the
26


cost
of
services
related
to
the
use
of
an
investigational
drug,
27


biological
product,
or
device
under
this
chapter.
28


3.
This
chapter
does
not
require
any
governmental
agency
29


to
pay
costs
associated
with
the
use,
care,
or
treatment
of
a
30


patient
with
an
investigational
drug,
biological
product,
or
31


device.
32


4.
This
chapter
does
not
require
a
hospital
licensed
under
33


chapter
135B
or
other
health
care
facility
to
provide
new
or
34


additional
services.
35


-3-


LSB
1642XC
(1)
86


tr/nh
3/
6





S.F.
_____


Sec.
5.
NEW
SECTION
.
144E.5
Heirs
not
liable
for
treatment
1


debts.
2


If
a
patient
dies
while
being
treated
by
an
investigational
3


drug,
biological
product,
or
device,
the
patient’s
heirs
are
4


not
liable
for
any
outstanding
debt
related
to
the
treatment
5


or
lack
of
insurance
due
to
the
treatment,
unless
otherwise
6


required
by
law.
7


Sec.
6.
NEW
SECTION


.
144E.6
Provider
recourse.
8


1.
The
board
of
medicine
created
under
chapter
147
shall
9


not
revoke,
fail
to
renew,
suspend,
or
take
any
action
10


against
a
physician’s
license
based
solely
on
the
physician’s
11


recommendations
to
an
eligible
patient
regarding
access
to
or
12


treatment
with
an
investigational
drug,
biological
product,
or
13


device.
14


2.
To
the
extent
consistent
with
federal
law,
an
entity
15


responsible
for
Medicare
certification
shall
not
take
action
16


against
a
physician’s
Medicare
certification
based
solely
on
17


the
physician’s
recommendation
that
a
patient
have
access
to
an
18


investigational
drug,
biological
product,
or
device.
19


Sec.
7.
NEW
SECTION


.
144E.7
State
interference.
20


An
official,
employee,
or
agent
of
this
state
shall
not
21


block
or
attempt
to
block
an
eligible
patient’s
access
to
22


an
investigational
drug,
biological
product,
or
device.
23


Counseling,
advice,
or
a
recommendation
consistent
with
medical
24


standards
of
care
from
a
licensed
physician
is
not
a
violation
25


of
this
section.
26


Sec.
8.
NEW
SECTION


.
144E.8
Private
cause
of
action.
27


1.
This
chapter
shall
not
create
a
private
cause
of
28


action
against
a
manufacturer
of
an
investigational
drug,
29


biological
product,
or
device
or
against
any
other
person
30


or
entity
involved
in
the
care
of
an
eligible
patient
using
31


the
investigational
drug,
biological
product,
or
device
32


for
any
harm
done
to
the
eligible
patient
resulting
from
33


the
investigational
drug,
biological
product,
or
device,
if
34


the
manufacturer
or
other
person
or
entity
is
complying
in
35


-4-


LSB
1642XC
(1)
86


tr/nh
4/
6







S.F.
_____


good
faith
with
the
terms
of
this
chapter
and
has
exercised
1


reasonable
care.
2


2.
This
chapter
shall
not
affect
any
mandatory
health
care
3


coverage
for
participation
in
clinical
trials
under
Title
XIII,
4


subtitle
1.
5


EXPLANATION
6


The
inclusion
of
this
explanation
does
not
constitute
agreement
with
7


the
explanation’s
substance
by
the
members
of
the
general
assembly.
8


This
bill,
titled
the
“Right
to
Try
Act”,
permits
9


manufacturers
of
investigational
drugs,
biological
products,
or
10


devices
to
make
available,
and
eligible
patients
with
terminal
11


illnesses
to
attempt
treatment
with,
an
investigational
12


drug,
biological
product,
or
device
as
long
as
they
provided
13


written
informed
consent.
The
bill
defines
the
terms
“eligible
14


patient”,
“terminal
illness”,
“investigational
drug,
biological
15


product,
or
device”,
and
“written
informed
consent”.
16


Under
the
bill,
an
eligible
patient’s
physician
must
17


acknowledge
that
the
patient’s
illness
is
terminal
and
18


recommend
the
patient
try
an
investigational
drug,
biological
19


product,
or
device.
The
patient’s
written
informed
consent
20


must
acknowledge
that
treatments
currently
approved
by
the
21


United
Stated
food
and
drug
administration
are
unlikely
to
22


prolong
the
patient’s
life.
It
must
identify
the
specific
23


treatment
sought
and
the
potential
best,
worst,
and
expected
24


results
from
the
treatment.
It
must
acknowledge
that
the
25


patient’s
insurance
is
not
required
to
pay
for
the
treatment
26


and
that
any
hospice
service
may
refuse
to
accept
the
patient
27


after
receiving
the
treatment.
It
must
also
acknowledge
28


that
expenses
will
be
credited
to
the
patient,
including
the
29


patient’s
estate,
unless
an
agreement
with
the
manufacturer
of
30


an
investigational
drug,
biological
product,
or
device
states
31


otherwise.
If
the
patient
dies
during
treatment,
the
patient’s
32


heirs
are
not
liable
for
any
remaining
debts
unless
otherwise
33


required
by
law.
34


The
manufacturer
of
an
investigational
drug,
biological
35


-5-


LSB
1642XC
(1)
86


tr/nh
5/
6



S.F.
_____


product,
or
device
may
charge
an
eligible
patient
or
provide
1


the
treatment
free
of
charge.
Governmental
entities
are
2


not
required
to
pay
costs
associated
with
the
use,
care,
or
3


treatment
of
a
patient
with
an
investigational
drug,
biological
4


product,
or
device.
The
bill
does
not
require
hospitals
5


licensed
under
chapter
135B
or
other
health
care
facilities
to
6


provide
new
or
additional
services.
7


The
board
of
medicine
shall
not
take
an
adverse
action
8


against
a
physician’s
license
solely
for
recommending
an
9


investigational
drug,
biological
product,
or
device
for
the
10


physician’s
eligible
patient.
The
bill
does
not
create
a
new
11


private
cause
of
action
against
any
person
or
entity
involved
12


in
the
care
of
an
eligible
patient
using
the
investigational
13


drug,
biological
product,
or
device
for
any
harm
done
to
the
14


patient
resulting
from
the
treatment
if
the
person
or
entity
15


is
complying
in
good
faith
with
the
terms
of
the
bill
and
has
16


exercised
reasonable
care.


17


-6-


LSB
1642XC
(1)
86


tr/nh
6/
6

